Patents by Inventor Michael Schraeml

Michael Schraeml has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11054425
    Abstract: In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases. In another aspect, the present disclosure provides glutamine-containing substrates (or Q-tag substrates) that are more resistant to proteases/clipping and therefore, more stable, than other Q-tag substrates, and their uses in substrate tags for cross-linking to an amine-donor tag via an isopeptide bond mediated by a microbial transglutaminase.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: July 6, 2021
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Thomas Albert, Frank Bergmann, Victor Lyamichev, Mohamed Yosry Hassan Mohamed, Tobias Oelschlaegel, Jigar Patel, Michael Schraeml, Wojtek Steffen, Thomas Streidl
  • Publication number: 20210155976
    Abstract: The present report relates to hybridizing single-stranded (ss-) oligonucleotides which entirely consist of locked nucleic acid (LNA) monomers. The present document shows hybridization experiments with pairs of entirely complementary ss-oligonucleotides which fail to form a duplex within a given time interval. The present report provides methods to identify such incompatible oligonucleotide pairs. In another aspect, the present report provides pairs of complementary ss-oligonucleotides which are capable of rapid duplex formation. The present report also provides methods to identify and select compatible oligonucleotide pairs. In yet another aspect the present report provides use of compatible oligonucleotide pairs as binding partners in binding assays, e.g. immunoassays.
    Type: Application
    Filed: December 18, 2020
    Publication date: May 27, 2021
    Inventors: Frank Bergmann, Dieter Heindl, Michael Schraeml, Johannes Stoeckel
  • Patent number: 10982007
    Abstract: A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: April 20, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Dieter Heindl, Christian Klein, Alfred Mertens, Volker Schmid, Michael Schraeml, Monika Soukupova, Michael Tacke
  • Publication number: 20210088511
    Abstract: Provided are nanopore-based methods, compositions, and systems for assessing analyte-ligand interactions and analyte concentration in a fluid solution. The compositions include an analyte detection complex that is associated with a nanopore to form a nanopore assembly, the analyte detection complex including an analyte ligand. As a first voltage is applied across the nanopore assembly, the analyte ligand is presented to an analyte in the solution. As a second voltage that is opposite in polarity to the first voltage is applied across the nanopore assembly, the analyte binds to the analyte. By comparing the total number of analyte-ligand binding pairs to a control binding count, the concentration of the analyte can be determined. In other examples, further increasing the second voltage can result in dissociation of the analyte-ligand pair, from which a dissociation voltage—and hence a dissociation constant—can be determined.
    Type: Application
    Filed: September 30, 2020
    Publication date: March 25, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Peter CRISALLI, Dmitriy GREMYACHINSKIY, Dieter HEINDL, Hannes KUCHELMEISTER, Michael SCHRAEML, Andrew TRANS
  • Publication number: 20210061924
    Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1.
    Type: Application
    Filed: October 13, 2020
    Publication date: March 4, 2021
    Inventors: Hartmut Duefel, Alfred Engel, Frank Kroner, Thomas Meier, Sandra Rutz, Michael Schraeml, Gloria Tabares, Ulrike Kurtkaya, Boris Pinchuk, Christina Zimmermann
  • Publication number: 20210009993
    Abstract: The present invention relates to a novel method of generating libraries of polynucleotides encoding a framework region and at least one adjacent complementarity determining region (CDR) of an antibody of interest. These libraries are suitable for use in affinity maturation procedures in order to obtain maturated antibodies with improved characteristics compared to the parent antibody.
    Type: Application
    Filed: September 9, 2020
    Publication date: January 14, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Frank Kroner, Michael Schraeml, Sarah Liedke
  • Publication number: 20210009668
    Abstract: The present invention relates to improved variant monoclonal antibodies binding to cardiac troponin T and having a better KD than the monoclonal antibody 12.1A11.11-7, produced by hybridoma clone 7.1 A 12.2-22 (ECACC 89060901) as deposited with European Collection of Animal Cell Cultures, GB.
    Type: Application
    Filed: September 9, 2020
    Publication date: January 14, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Frank Kroner, Michael Schraeml, Sarah Liedke
  • Patent number: 10877030
    Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: December 29, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Publication number: 20200371102
    Abstract: In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases. In another aspect, the present disclosure provides glutamine-containing substrates (or Q-tag substrates) that are more resistant to proteases/clipping and therefore, more stable, than other Q-tag substrates, and their uses in substrate tags for cross-linking to an amine-donor tag via an isopeptide bond mediated by a microbial transglutaminase.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Inventors: Thomas Albert, Frank Bergmann, Victor Lyamichev, Mohamed Yosry Hassan Mohamed, Tobias Oelschlaegel, Jigar Patel, Michael Schraeml, Wojtek Steffen, Thomas Streidl
  • Patent number: 10808038
    Abstract: The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 20, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Birgit Bossenmaier, Richard Buick, Stefan Dengl, Michael Gerg, Carmen Peess, Wolfgang Schaefer, Michael Schraeml, Claudio Sustmann
  • Patent number: 10788495
    Abstract: In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 29, 2020
    Assignee: ROCHE SEQUENCING SOLUTIONS, INC.
    Inventors: Thomas Albert, Frank Bergmann, Victor Lyamichev, Jigar Patel, Michael Schraeml, Wojtek Steffen, Thomas Streidl
  • Publication number: 20200277406
    Abstract: A binding agent of the Formula A-a?:a-S-b:b?-B:X(n), wherein A as well as B is a monovalent binder, a?:a as well as b:b? is a binding pair wherein a? and a do not interfere with the binding of b to b? and vice versa, S is a spacer of at least 1 nm in length, :X denotes a functional moiety bound either covalently or via a binding pair to at least one of a?, a, b, b? or S, (n) is an integer and at least 1, — represents a covalent bond, and the linker a-S-b has a length of 6 to 100 nm. Also disclosed are methods of producing such binding agent and certain uses thereof.
    Type: Application
    Filed: March 17, 2020
    Publication date: September 3, 2020
    Inventors: Andreas Gallusser, Dieter Heindl, Michael Schraeml, Christoph Seidel, Herbert von der Eltz
  • Publication number: 20200249231
    Abstract: In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases. In another aspect, the present disclosure provides glutamine-containing substrates (or Q-tag substrates) that are more resistant to proteases/clipping and therefore, more stable, than other Q-tag substrates, and their uses in substrate tags for cross-linking to an amine-donor tag via an isopeptide bond mediated by a microbial transglutaminase.
    Type: Application
    Filed: February 7, 2020
    Publication date: August 6, 2020
    Inventors: Thomas Albert, Frank Bergmann, Victor Lyamichev, Mohamed Yosry Hassan Mohamed, Tobias Oelschlaegel, Jigar Patel, Michael Schraeml, Wojtek Steffen, Thomas Streidl
  • Publication number: 20200223912
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: September 9, 2019
    Publication date: July 16, 2020
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
  • Publication number: 20200207874
    Abstract: Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.
    Type: Application
    Filed: December 5, 2019
    Publication date: July 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael GERG, Dieter HEINDL, Gerhard NIEDERFELLNER, Wolfgang SCHAEFER, Michael SCHRAEML, Michael TACKE
  • Patent number: 10647765
    Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: May 12, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Herbert Andres, David Casagolda Vallribera, Hartmut Duefel, Michael Gerg, Christian Scholz, Michael Schraeml
  • Publication number: 20200141930
    Abstract: The present invention relates to a method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto.
    Type: Application
    Filed: January 6, 2020
    Publication date: May 7, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Schraeml, Markus Roessler, Michael Gerg
  • Patent number: 10633460
    Abstract: A binding agent of the Formula A-a?:a-S-b:b?-B:X(n), wherein A as well as B is a monovalent binder, a?:a as well as b:b? is a binding pair wherein a? and a do not interfere with the binding of b to b? and vice versa, S is a spacer of at least 1 nm in length, :X denotes a functional moiety bound either covalently or via a binding pair to at least one of a?, a, b, b? or S, (n) is an integer and at least 1, — represents a covalent bond, and the linker a-S-b has a length of 6 to 100 nm. Also disclosed are methods of producing such binding agent and certain uses thereof.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: April 28, 2020
    Assignee: Roche Diagnostic Operations, Inc.
    Inventors: Andreas Gallusser, Dieter Heindl, Michael Schraeml, Christoph Seidel, Herbert von der Eltz
  • Patent number: 10626177
    Abstract: The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, David Casagolda Vallribera, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Patent number: 10564151
    Abstract: The present invention relates to a method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: February 18, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Michael Schraeml, Markus Roessler, Michael Gerg